Kimberly Vanover
Engrail Therapeutics INC · Intra-Cellular Therapies, Inc. · Intra-Cellular Therapies, Inc. (ITI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kimberly Vanover as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06653296 · A Dose-Response Safety Study of ENX-102 in Patients With GADEngrail Therapeutics INC · completed · General Anxiety Disorder · study director
- Ph1/Ph2NCT03257046 · Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's DiseaseIntra-Cellular Therapies, Inc. · completed · Parkinson Disease · study director
- Ph3NCT02469155 · A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of TreatmentIntra-Cellular Therapies, Inc. · completed · Schizophrenia · study director
- Ph2NCT02288845 · Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable SchizophreniaIntra-Cellular Therapies, Inc. · completed · Schizophrenia · study director
- Ph3NCT02282761 · A Trial to Assess the Antipsychotic Efficacy of ITI-007Intra-Cellular Therapies, Inc. · completed · Schizophrenia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:51 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.JAMA Psychiatry · 2020104 citationsRCR 7.3
- A small randomized pilot study of a workplace mindfulness-based intervention for surgical intensive care unit personnel: effects on salivary α-amylase levels.J Occup Environ Med · 2015100 citationsRCR 6.2
- Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.Am J Psychiatry · 202180 citationsRCR 6.7
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.Biol Psychiatry · 201676 citationsRCR 3.6
- 74 citationsRCR 2.7
- Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.Neuropsychopharmacology · 201958 citationsRCR 3.1
- PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.Int J Neuropsychopharmacol · 200841 citationsRCR 1.3
- 41 citationsRCR 1.4
- Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.J Clin Pharmacol · 200732 citationsRCR 1.0
- Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.Bipolar Disord · 202323 citationsRCR 3.8